# Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab

> **NCT04770376** · — · UNKNOWN · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 150 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **OTHER:** Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.

## Key facts

- **NCT ID:** NCT04770376
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-12
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04770376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04770376, "Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04770376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*